In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

C-Suite Speaks

Working With Patients To Use AI Against Rare Diseases

Tim Guilliams, CEO of Healx, talks about the company’s mission of creating from existing drugs new options for rare disease patients. The company is using artificial intelligence to find combination treatments against rare conditions, while working closely with patient groups as key partners in the development process. The goal: faster development timelines and cheaper therapies for patients.

Bringing Precision To Solid Tumor Targets

Achilles Therapeutics is betting that its clonal neoantigen-targeting T cell (cNeT) products, combined with an industrial scale advanced manufacturing capability and predictive bioinformatics platform, will have a transformational impact on patients with solid tumors and metastasized cancer.

Challenges And Opportunities At The New Cytiva

In 2019, more than 75% of the biological therapies approved by the FDA used technologies developed by GE Healthcare Life Sciences for manufacturing. Following the completion of a $21.9bn acquisition by Danaher, the company has rebranded to Cytiva. In Vivo speaks with CEO Emmanuel Ligner to learn more about his vision for the new company and the impact of COVID-19. 

Stick To The Plan – But Be Ready To Change

Know your strengths, surround yourself with experts and ensure your solution “does what it says on the tin.” These are among the guiding principles of Christophe Bancel, co-founder of France’s biopolymer innovator TISSIUM, a health care start-up on the cusp of commercialization.

What Does AI Excellence Look Like In Big Pharma?

Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.

Narasimhan's Culture Club On Song At Novartis

Taking over at the Swiss firm as CEO in 2018, Vas Narasimhan set about creating an "inspired, curious and unbossed organization." Two years on, he has put the spotlight on several initiatives that are up and running on a number of fronts to achieve that goal.

Discussing The Past, Present And Future Of Cell And Gene Therapies

Founding CEO of the UK’s Cell and Gene Therapy Catapult, Keith Thompson, will retire from the company this year. He looks back on the last eight years of progress for CGT Catapult and the  advanced therapies sector – and provides words of wisdom for the challenges still to come.

The Only Way Is Nasdaq – Part Two

It has been a bumpy ride for some of the (still modest) number of European biotechs listed on Nasdaq, for various reasons. Yet most expect the direct-to-Nasdaq trend to continue. Europe’s public markets simply cannot compete.

Meindert Boysen On What Companies Should Expect From NICE

In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.

The Only Way Is Nasdaq – Part One

The US Nasdaq exchange has become the only option for ambitious UK and European biotechs.

Investing In People: Aligning VCs And Today’s Entrepreneurs

In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.

AstraZeneca's Fredrickson On Its Cancer Ambitions

Just over a year ago, AstraZeneca at last returned to growth and set about a reorganization that placed oncology at the heart of its plans for continued success. In Vivo talked to the executive vice-president of its Oncology Business Unit David Fredrickson about how the company hopes to become a major cancer player.

CNS Biomarkers: Monument Targets Schizophrenia, Anxiety And Cognitive Decline

Steven Powell, chair of the board at Cambridge Cognition, talks about the group’s latest spin-off company, Monument Therapeutics.

Internal Manufacturing Capabilities Are Critical To Level-Up eTheRNA

A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.

C-Suite Snippets: Meindert Boyson's NICE Advice

In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.

AstraZeneca Veteran Returns To Biotech With Fresh Goals For A New Decade

In December 2019, Jane Osbourn became the first woman to win Scrip’s Life Time Achievement Award for her work in human monoclonal antibody drug research.

UsernamePublicRestriction

Register